[Advanced carcinoma of the prostate (stages C and D). Mortality within 12 months of the initiation of hormonal therapy].
Seventy-three patients with stage C and D prostatic carcinoma were treated with hormonotherapy. During a mean follow-up of 27 +/- 17.8 months, 30 tumour-related deaths were registered. The patients in the G3 subset suffered a 35.7% early death rate versus a 10.1% rate of G1-2 ones. This difference is significant (p = 0.0102). Nevertheless the Authors' opinion is that G3 patients should not be given a more aggressive treatment initially apart from the case of a controlled trial.
Ferraris
V
V
Divisione di Urologia, USSL n. 76, Casale Monferrato, Alessandria.
Vitale
I
I
Pisano
P F
PF
Buffa
G
G
D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D005485:Flutamide / Q000627:therapeutic use*; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D016019:Survival Analysis; D015996:Survival Rate
D017273:Goserelin; D005485:Flutamide
Carcinoma avanzato della prostata (stadi C e D). Mortalità entro 12 mesi dall'inizio della terapia ormonale.